NYX-2925 Lowers Marker of Pain Severity in Fibromyalgia Patients, Early Phase 2 Trial Results Show
News
The chronic pain treatment candidate NYX-2925 lowered levels of a brain activity marker called glutamine (Glx), associated with pain severity, according to preliminary results of a Phase 2 pilot trial ... Read more